Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan
Financial results Revenues were $86,604, an increase of $4,007 or 5% over the same period in prior year driven by the growth of our key promoted products offset by our mature branded generic products. Gross margin was $41,699 or 48% compared to $40,762 or …